Chemotherapy (i.e., Gemcitabine, Docetaxel Plus Gemcitabine, Doxorubicin, or Trabectedin) for Inoperable, Locally Advanced, Recurrent, or Metastatic Uterine Leiomyosarcoma

This clinical practice guideline discusses the use of chemotherapy for the treatment of locally advanced, recurrent, or metastatic uterine leiomyosarcoma (LMS) in adult women. Gemcitabine, docetaxel plus gemcitabine, doxorubicin, and trabectedin are compared, and the use of granulocyte growth factor (G-CSF) is considered. Outcomes of interest include overall and progression-free survival time, tumour response rate, stable disease rate, progressive disease rate, and toxicity.